Better Scans Spot Hidden Inflammation in MS Patients
FRIDAY, April 26, 2024 -- Advanced scanning techniques can find hidden inflammation in the brains of multiple sclerosis (MS) patients, a new study shows.This “smoldering” inflammation detected by positron emission tomography (PET) brain scans... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 26, 2024 Category: General Medicine Source Type: news
Right brain: the unraveling - Michaelson NM.
"The Unraveling" is a personal reflection from my perspective as a new fellow in Multiple Sclerosis/Neuroimmunology on the impact of multiple sclerosis on patients and their loved ones. I compare my more recent patient encounters with past experiences work... (Source: SafetyLit)
Source: SafetyLit - April 26, 2024 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
The association of fear of falling and falls with sedentary behavior in people with multiple sclerosis - Farber AE, Menascu S, Kalron A.
OBJECTIVE: Sedentary behavior, falls, and fear of falling (FoF) are specific concerns for people with MS (pwMS). Considering the relatively high incidence and potential linkage, it is surprising that this triple relationship has as yet not been extensively... (Source: SafetyLit)
Source: SafetyLit - April 25, 2024 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Investor Update - April 24, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Media News - April 24, 2024 Category: Pharmaceuticals Source Type: news
Alzheimer's Drug Skepticism; Safeguarding Brain Data; Benefits of Stimulating Jobs
(MedPage Today) -- Physicians treating Alzheimer's patients discussed why they're hesitant to prescribe lecanemab (Leqembi). (Reuters)
Researchers reviewed the role of neurofilament proteins in multiple sclerosis (MS), Alzheimer's disease, frontotemporal... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 23, 2024 Category: Neurology Source Type: news
Hyperfine highlights abstracts to be presented at ISMRM 2024
Hyperfine is highlighting 17 ultralow-field MRI-related abstracts to be presented at the 2024 International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting, to be held from May 4 to 9 in Singapore.
The abstracts span a variety of use cases, including two that highlight the utility of brain images acquired with the ultralow-field Swoop Portable MR Imaging system to aid physicians in screening for various biomarkers and monitoring disease progression unique to neurodegenerative diseases. These include Alzheimer’s disease and multiple sclerosis. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 23, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Novel Drug Made of Gold Nanocrystals Appears Safe in Multiple Sclerosis
(MedPage Today) -- DENVER -- An oral suspension of clean-surfaced gold nanocrystals known as CNM-Au8 was safe and well-tolerated in patients with stable relapsing-remitting multiple sclerosis (MS) and chronic optic neuropathy, the long-term open... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 22, 2024 Category: Neurology Source Type: news
Multiple Sclerosis Predicted by Autoantibody Signature
(MedPage Today) -- A specific autoantibody signature was seen in a subset of people with multiple sclerosis (MS) long before clinical symptoms appeared, blood samples showed.
A distinct set of autoantibodies emerged in approximately 10% of MS... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 20, 2024 Category: Neurology Source Type: news
ICI Tx in MS Patients With Comorbid Cancer: Reassuring Data ICI Tx in MS Patients With Comorbid Cancer: Reassuring Data
There is no increased relapse risk in patients with multiple sclerosis and comorbid cancer who are taking checkpoint inhibitor therapy, results of a small study suggest.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 19, 2024 Category: Cancer & Oncology Tags: Neurology & Neurosurgery News Source Type: news
Blood Test Might Someday Diagnose Early MS
FRIDAY, April 19, 2024 -- An early marker of multiple sclerosis could help doctors figure out who will eventually fall prey to the degenerative nerve disease, a new study says.In one in 10 cases of MS, the body begins producing a distinctive set of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 19, 2024 Category: General Medicine Source Type: news
Ocrelizumab Trial Fills Research Gap for Black, Hispanic MS Patients
(MedPage Today) -- DENVER -- Among Black/African American and Hispanic/Latino patients with relapsing multiple sclerosis (MS) in the phase IV CHIMES trial, half achieved a combined measure for no evidence of disease activity (NEDA) with ocrelizumab... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 18, 2024 Category: American Health Source Type: news
Pediatric traumatic brain injury and early age multiple sclerosis in Finland: a nationwide register-based cohort study - Laaksonen J, Ponkilainen V, Kuitunen I, M öttönen J, Mattila VM.
OBJECTIVE: Examine the link between pediatric traumatic brain injury (pTBI) and early-onset multiple sclerosis in Finland. METHODS: Conducted nationwide register study (1998-2018) with 28,750 pTBI patients (... (Source: SafetyLit)
Source: SafetyLit - April 18, 2024 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Roche ’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III...
Source: Roche Media News - April 17, 2024 Category: Pharmaceuticals Source Type: news
High-Efficacy Therapy Cuts Disability Progression in Pediatric MS
FRIDAY, April 12, 2024 -- Treatment of pediatric-onset relapsing-remitting multiple sclerosis with high-efficacy therapy reduces the risk for transition across disability states, according to a study published in the May issue of The Lancet Child... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2024 Category: Pharmaceuticals Source Type: news
